Company profile for Cellular Biomedicine Group

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

A clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancers and stem cell therapies for degenerative diseases. Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapies for the treatment of cancers and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in Ch...
A clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancers and stem cell therapies for degenerative diseases. Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapies for the treatment of cancers and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1345 Avenue of the Americas, 11th Floor New York, NY 10105
Telephone
Telephone
+1 347 905 5663
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/nektar-therapeutics-announces-new-clinical-study-collaboration-with-cellular-biomedicine-group-inc-to-evaluate-nktr-255-in-combination-with-c-til051-in-advanced-non-small-cell-lung-cancer-301939838.html

PR NEWSWIRE
27 Sep 2023

https://www.businesswire.com/news/home/20230511005473/en

BUSINESSWIRE
11 May 2023

https://www.prnewswire.com/news-releases/cbmg-receives-fda-regenerative-medicine-advanced-therapy-and-fast-track-designations-for-bi-specific-anti-cd19cd20-car-t-cell-therapy-for-relapsedrefractory-b-cell-non-hodgkin-lymphoma-301459134.html

PRNEWSWIRE
12 Jan 2022

https://www.prnewswire.com/news-releases/cbmg-receives-fda-clearance-of-ind-application-for-bi-specific-anti-cd19cd20-car-t-cell-therapy-for-relapsedrefractory-b-cell-non-hodgkin-lymphoma-301443153.html

PRNEWSWIRE
13 Dec 2021

https://www.prnewswire.com/news-releases/cbmg-holdings-completes-120-million-in-series-a-funding-accelerating-development-of-car-t-therapy-pipelines-and-rd-for-innovative-solid-tumor-therapies-301388836.html

PRNEWSWIRE
30 Sep 2021

https://www.biospace.com/article/releases/cellular-biomedicine-group-inc-announces-completion-of-merger/?s=79

BIOSPACE
19 Feb 2021

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty